Company intelligence / Profile preview

Biond Biologics

Ownership: Private
Development stage: Phase 1

Overview

Biond Biologics has advanced two main immunotherapy candidates, BND‑22 and BND‑35, into Phase 1/2 clinical trials in patients with advanced solid tumors. Both are novel immune checkpoint inhibitors targeting previously untapped immune evasion mechanisms. Early results focus on safety, tolerability, pharmacokinetics/dynamics, and preliminary anti-tumor activity. The company also has several preclinical programs leveraging its INspire platform to target both intra‑ and extracellular pathways relevant to cancer immunology.[5][6]

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)Drug conjugatesNanobodies[8]
Industry: Biotech

Drug pipeline

6 assets

BND-22

5 more assets in the full pipeline.

Request access →

Partnerships

Sanofi – partnered on BND–22 with $125M upfront payment plus up to $1 billion in milestones and royalties.[7]

Beyond the preview

Go deeper on Biond Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biond Biologics.

Explore the full profile